MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.

Sudarshan R IyerIgor OdintsovAdam J Schoenfeld Evan Siau Marissa S Mattar Elisa De StanchinaInna KhodosAlexander E DrilonGregory J RielyMarc LadanyiRomel SomwarMonika A Davare

Published in: Molecular cancer research : MCR (2022)

This study functionally characterizes MYC overexpression as a novel form of therapeutic resistance to ROS1 tyrosine kinase inhibitors in non-small cell lung cancer and proposes rational combination treatment strategies.

Keyphrases

transcription factor
cell death
dna damage
reactive oxygen species
cell proliferation
oxidative stress
chronic myeloid leukemia